Pharmacokinetic and pharmacodynamics of xylazine administered to exercised thoroughbred horses.

The research aims to study the effects and presence of xylazine, a horse tranquilizer, in thoroughbred horses, focusing on its detection after 24 hours of administration. The results suggest that the drug exhibits a prolonged presence, thus stricter withdrawal times, beyond current regulations, are recommended to avoid unintended positive drug tests in performance horses.

Study Methodology

• The test subjects were sixteen adult Thoroughbred horses that had undergone exercise. Each horse was administered a single intravenous dose of 200 mg of xylazine.
• Blood and urine samples were taken at the start of the experiment and at various times for a period of up to 96 hours.
• The samples collected were analyzed using liquid chromatography tandem mass spectrometry in order to detect xylazine concentrations.

Results and Findings

• The analysis indicated that xylazine concentrations fit best in a 3-compartment model.
• Key pharmacokinetic parameters such as systemic clearance, volume of distribution at steady state, and beta half-life and gamma half-life were calculated.
• Observed effects of xylazine, post administration, included sedation (evidenced by decreased movement and heart rate) and an increase in glucose concentrations. These effects lasted for about 45 minutes and 1 hour, respectively.
• Drug impact measurements such as EC50 (the concentration of the drug which gives half-maximal response) and Emax (maximum effect) were also noted for heart rate, atrioventicular block, chin-to-ground distance and glucose concentration.

Conclusions

• According to the researchers, the pharmacokinetic parameters differ from previously reported data. They found a prolonged detection time for xylazine.
• The study suggested that an extended withdrawal time, exceeding current regulatory recommendations, is necessary to avoid unintentional positive drug tests related to performance horses.

This research works towards ensuring fair practices in horse racing or horse performance events, providing comprehensive data on xylazine, and asking for revisions to be made in existing regulations. It emphasizes the prolonged presence of the drug in the horse’s system, which could lead to inadvertent positives in drug tests.